Navin Fluorine International Limited (NFIL) has announced a significant financial move involving its wholly-owned subsidiary, Navin Fluorine Advanced Sciences Limited (NFASL). The subsidiary has allotted preference shares worth ₹200 crore to its parent company, a strategic decision aimed at strengthening the group's financial position.

Details of the Allotment

According to the company's filing with the stock exchanges, NFASL's Board of Directors has approved the allotment of 19,99,99,997 Non-Convertible, Non-Cumulative, Non-Participating, Redeemable Preference Shares to NFIL. These preference shares have a face value of ₹10 each, totaling ₹199,99,99,970.

Terms of the Preference Shares

The preference shares come with the following key features:

• 8% dividend rate
• Non-convertible nature
• Non-cumulative and non-participating structure
• Redeemable at the issuer's discretion

Purpose of the Allotment

The primary objectives of this financial transaction are:

1. Repayment of NFASL's external debts
2. Reduction of consolidated leverage levels for the Navin Fluorine group

This move is expected to improve the overall financial health of both NFASL and its parent company, NFIL.

About NFASL

Navin Fluorine Advanced Sciences Limited, incorporated on February 6, 2020, is a key player in the chemicals industry, focusing on fluorochemicals. The company has shown significant growth since its inception:

As of March 31, 2025, NFASL reported a profit after tax of ₹49.93 crores and a net worth of ₹742.64 crores.

Implications for Investors

This transaction is classified as a related party transaction, given that NFASL is a wholly-owned subsidiary of NFIL. However, the company has affirmed that the transaction is conducted on an arm's length basis, ensuring fairness and transparency for all stakeholders.

The allotment of preference shares is expected to have a positive impact on the group's financial structure by reducing external debt and improving leverage ratios. This strategic move may enhance investor confidence in Navin Fluorine's long-term financial stability and growth prospects.

As the chemical sector continues to evolve, Navin Fluorine's proactive approach to financial management could position it well for future opportunities and challenges in the fluorochemicals market.

Navin Fluorine International Limited , a prominent player in the fluorochemicals industry, has announced significant leadership changes in its Contract Development and Manufacturing Organization (CDMO) Business division, signaling a new chapter for the company's strategic growth.

Departure of Current CEO

Mr. Rajendra Sahu, the current CEO of the CDMO Business, has tendered his resignation to pursue career opportunities elsewhere. His tenure with Navin Fluorine International will conclude on September 20, 2025, marking the end of his leadership in this crucial division.

Appointment of New CEO

In a strategic move to ensure a smooth transition and continued growth, Navin Fluorine International has appointed Dr. Vijay Kaiwar as the CEO Designate of the CDMO Business. Dr. Kaiwar will assume full CEO responsibilities effective September 21, 2025, bringing with him a wealth of experience and expertise to the role.

Dr. Vijay Kaiwar's Profile

Dr. Kaiwar joins Navin Fluorine International with an impressive background:

• Nearly 30 years of experience in CDMO and API businesses
• Specialization in Chemistry and Biotechnology
• Leadership exposure across multiple functions, including R&D, Technology Transfer, Operations, Projects, Manufacturing, EHS, and Business Development
• Senior leadership roles at renowned companies such as Anthem Biosciences, Sun Pharma, Aurobindo Pharma, Jubilant Organosys, and Atul Limited
• Strong partnerships with leading global pharmaceutical and biotech companies
• Expertise in regulatory affairs and a broad spectrum of technologies

Educational Background

Dr. Kaiwar's academic credentials further underscore his expertise in the field:

• Ph.D. in Organic Chemistry from IICT Hyderabad
• Post-Doctoral Fellowship from King's College, London

Impact on Navin Fluorine International

The appointment of Dr. Kaiwar is expected to bring fresh perspectives and deep industry knowledge to Navin Fluorine International's CDMO Business. His extensive experience in building partnerships with global pharmaceutical clients and expertise in various advanced technologies aligns well with the company's focus on innovation and growth in the CDMO sector.

This leadership transition comes at a time when the CDMO industry is experiencing significant growth and transformation. Dr. Kaiwar's diverse skill set and experience in managing high-performing teams are likely to be valuable assets as Navin Fluorine International seeks to strengthen its position in the global CDMO market.

The company's proactive approach in announcing these changes well in advance demonstrates its commitment to ensuring a smooth transition and maintaining stakeholder confidence. As Navin Fluorine International embarks on this new phase under Dr. Kaiwar's leadership, the industry will be watching closely to see how these changes shape the company's future trajectory in the competitive CDMO landscape.